Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain

References

• Lavrentaki A, Paluzzi A, Wass JA, et al. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4–9.
   PubMed Web of Science ®Google Scholar
• Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004;151(4):439–446.
   PubMed Web of Science ®Google Scholar
• Sesmilo G, Gaztambide S, Venegas E, et al. REA investigators. Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA). Pituitary. 2013;16(1):115–121.
   PubMed Web of Science ®Google Scholar
• Cordido F, García Arnés JA, Marazuela Aspiroz M, et al. grupo de Neuroendocrinología de la Sociedad Española de Endocrinología y Nutrición. [Practical guidelines for diagnosis and treatment of acromegaly. Grupo de Neuroendocrinología de la Sociedad Española de Endocrinología y Nutrición]. Endocrinol Nutr. 2013;60(8):457.e1–457.e15.
   PubMedGoogle Scholar
• Katznelson L, Laws ER Jr, Melmed S, et al. Endocrine society. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–3951.
   PubMed Web of Science ®Google Scholar
• Sesmilo G, Webb SM. Neuroendocrinology group of the spanish society of endocrinology and nutrition. Twelve years of the Spanish acromegaly registry: a historical view of acromegaly management in Spain. Endocrinol Nutr. 2010;57(2):39–42.
   PubMedGoogle Scholar
• EMA. Ficha Técnica Somavert (Pegvisomant). 2016. [Cited 2018 Jun]. [ Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000409/WC500054629.pdf
   Google Scholar
• EMA. Ficha Técnica Signifor Pasireotida). 2016. [Cited 2018 Jun]. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002052/WC500128056.pdf.
   Google Scholar
• Melmed S, Bronstein MD, Chanson P, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552–561.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide C2402 study group. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–884. .
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171–1177.
   PubMed Web of Science ®Google Scholar
• López Bastida J, Oliva J, Antoñanzas F, et al. [A proposed guideline for economic evaluation of health technologies]. Gac Sanit. 2010;24(2):154–170.
   PubMed Web of Science ®Google Scholar
• INE. Defunciones por edad, mes y sexo. Datos provisionales Año 2015 2016. 2015. [Cited 2018 Jun]. Available from: http://www.ine.es.
   Google Scholar
• Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159(2):89–95.
   PubMed Web of Science ®Google Scholar
• Bernabeu I, Pico A, Venegas E, et al. Spanish ACROSTUDY group. Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. Pituitary. 2016;19(2):127–137. .
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295):1754–1759.
   PubMed Web of Science ®Google Scholar
• Brazzelli M, Cruickshank M, Kilonzo M, et al. Clinical effectiveness and cost-effectiveness of cholecystectomy compared with observation/conservative management for preventing recurrent symptoms and complications in adults presenting with uncomplicated symptomatic gallstones or cholecystitis: a systematic review and economic evaluation. Health Technol Assess. 2014;18(55):1–101.
   Web of Science ®Google Scholar
• García-Soidán FJ, Villoro R, Merino M, et al. Estado de salud, calidad de vida y utilización de recursos sanitarios de los pacientes con diabetes mellitus en España. Medic Fam. 2017;43(6):416–424.
   Google Scholar
• Rowles SV, Prieto L, Badia X, et al. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab. 2005;90(6):3337–3341.
   PubMed Web of Science ®Google Scholar
• Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the global burden of disease study 2010. Lancet. 2012;380(9859):2129–2143.
   PubMed Web of Science ®Google Scholar
• Ferreira CNRC, Santana CF Acromegaly patients with inadequate response to maximum dose octreotide-lar who progress to treatment with pegvisomant: economic evaluation and incremental budget impact analysis from the public perspective to são paulo state. ISPOR 5th Latin America conference; September 2015; Santiago de Chile: ISPOR; 2015.
   Google Scholar
• Llibre-Codina JM, Casado-Gómez MA, Sánchez-de la Rosa R, et al. [Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients]. Enferm Infecc Microbiol Clin. 2007;25(2):98–107.
   PubMed Web of Science ®Google Scholar
• Registro de altas. CIE9 MC CMBD 2013 [Internet]. 2013. [Cited 2018 Nov 04]. Available from: http://pestadistico.inteligenciadegestion.msssi.es
   Google Scholar
• Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102–152.
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Grasso LF, et al. Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. Eur J Endocrinol. 2011;165(5):713–721.
   PubMed Web of Science ®Google Scholar
• Davi‘ MV, Dalle Carbonare L, Giustina A, et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol. 2008;159(5):533–540.
   PubMed Web of Science ®Google Scholar
• Andreu AL, Chiner E, Sancho-Chust JN, et al. Effect of an ambulatory diagnostic and treatment programme in patients with sleep apnoea. Eur Respir J. 2012;39(2):305–312.
   PubMed Web of Science ®Google Scholar
• Ballesta M, Carral F, Olveira G, et al. Economic cost associated with type II diabetes in Spanish patients. Eur J Health Econ. 2006;7(4):270–275.
   PubMedGoogle Scholar
• Delgado JF, Oliva J, Llano M, et al. Health care and nonhealth care costs in the treatment of patients with symptomatic chronic heart failure in Spain. Rev Esp Cardiol. 2014;67(8):643–650.
   PubMed Web of Science ®Google Scholar
• Montes-Santiago J, Rodil V, Formiga F, et al. Working group on heart failure and atrial fibrillation of the Spanish Society of Internal Medicine (SEMI). Features and costs of patients admitted for cardiac arrhythmias in Spain. Rev Clin Esp. 2013;213(5):235–239.
   PubMedGoogle Scholar
• Sicras-Mainar A, Navarro-Artieda R. [Cost of arterial hypertension according to levels of morbidity in primary care setting]. Med Clin. 2009;133(8):290–295.
   PubMed Web of Science ®Google Scholar
• Freda PU, Gordon MB, Kelepouris N, et al. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr Pract. 2015;21(3):264–274. .
   PubMed Web of Science ®Google Scholar
• Eckhardt R, Ulam S, von Neumann J, and the Monte Carlo method. Los Alamos Sci. 1987;15(6):131-146.
   Google Scholar
• Muhammad A, van der Lely AJ, Delhanty PJD, et al. Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE study). J Clin Endocrinol Metab. 2018;103(2):586–595.
   PubMed Web of Science ®Google Scholar
• Feola T, Cozzolino A, Simonelli I, et al. Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab. 2019. DOI:10.1210/jc.2018-02281
   PubMed Web of Science ®Google Scholar
• Vallejo-Torres L, García-Lorenzo B, Castilla I, et al. Valor Monetario de un Año de Vida Ajustado por Calidad: estimación empírica del coste de oportunidad en el Sistema Nacional de Salud.: ministerio de Sanidad, Servicios Sociales e Igualdad. Servicio de Evaluacio´n del Servicio Canario de la Salud. 2015.
   Google Scholar
• Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36–42.
   PubMed Web of Science ®Google Scholar
• Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? Qjm. 2005;98(11):829–836.
   PubMed Web of Science ®Google Scholar
• Picavet E, Dooms M, Cassiman D, et al. Drugs for rare diseases: influence of orphan designation status on price. Appl Health Econ Health Policy. 2011;9(4):275–279.
   PubMedGoogle Scholar
• Maione L, Brue T, Beckers A, et al. French acromegaly registry group. Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. Eur J Endocrinol. 2017;176(5):645–655.
   PubMed Web of Science ®Google Scholar
• Margusino-Framiñán L, Pertega-Diaz S, Pena-Bello L, et al. Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome. Eur J Intern Med. 2015;26(9):736–741.
   PubMed Web of Science ®Google Scholar
• Didoni G, Grottol S, Gasco V, et al. Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest. 2004;27(11):1034–1039.
   PubMed Web of Science ®Google Scholar
• Luque-Ramírez M, Paramo C. Varela da Costa C, García-Mayor RV. Cost of management of invasive growth hormone-secreting macroadenoma. J Endocrinol Invest. 2007;30(7):541–545.
   PubMed Web of Science ®Google Scholar
• Wilson LS, Shin JL, Ezzat S. Longitudinal assessment of economic burden and clinical outcomes in acromegaly. Endocr Pract. 2001;7(3):170–180.
   PubMedGoogle Scholar
• Valentim J, Passos V, Mataveli F, et al. Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil. Arq Bras Endocrinol Metabol. 2008;52(9):1452–1460.
   PubMedGoogle Scholar
• Roset M, Merino-Montero S, Luque-Ramírez M, et al. Spanish group of the OASIS study. Cost of clinical management of acromegaly in Spain. Clin Drug Investig. 2012;32(4):235–245.
   PubMed Web of Science ®Google Scholar
• Leonart LP, Borba HHL, Ferreira VL, et al. Cost-effectiveness of acromegaly treatments: a systematic review. Pituitary. 2018;21(6):642–652.
   PubMed Web of Science ®Google Scholar
• Orlewska E, Stępień R, Orlewska K. Cost-effectiveness of somatostatin analogues in the treatment of acromegaly. Expert Rev Pharmacoecon Outcomes Res. 2019;19(1):15–25.
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Roelfsema F, Pereira AM, et al. Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly. Expert Rev Pharmacoecon Outcomes Res. 2009;9(3):223–234.
   PubMedGoogle Scholar
• Shimon I, Adnan Z, Gorshtein A, et al. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine. 2018 Nov;62(2):448–455.
   PubMed Web of Science ®Google Scholar
• Duan L, Huang M, Yan H, et al. Cost-effectiveness analysis of two therapeutic schemes in the treatment of acromegaly: a retrospective study of 168 cases. J Endocrinol Invest. 2015;38(7):717–723.
   PubMed Web of Science ®Google Scholar